Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status

Amy R. Cameron, Vicky L. Morrison, Daniel Levin, Mohapradeep Mohan, Calum Forteath, Craig Beall, Alison D. McNeilly, David J.K. Balfour, Terhi Savinko, Aaron K.F. Wong, Benoit Viollet, Kei Sakamoto, Susanna C. Fagerholm, Marc Foretz, Chim C. Lang, Graham Rena

Rationale: The diabetes mellitus drug metformin is under investigation in cardiovascular disease, but the molecular mechanisms underlying possible benefits are poorly understood.

Objective: Here, we have studied anti-inflammatory effects of the drug and their relationship to antihyperglycemic properties.

Methods and Results: In primary hepatocytes from healthy animals, metformin and the IKKβ (inhibitor of kappa B kinase) inhibitor BI605906 both inhibited tumor necrosis factor-α–dependent IkB degradation and expression of proinflammatory mediators interleukin-6, interleukin-1β, and CXCL1/2 (C-X-C motif ligand 1/2). Metformin suppressed IKKα/β activation, an effect that could be separated from some metabolic actions, in that BI605906 did not mimic effects of metformin on lipogenic gene expression, glucose production, and AMP-activated protein kinase activation. Equally AMP-activated protein kinase was not required either for mitochondrial suppression or IkB degradation. Consistent with discrete anti-inflammatory actions, in macrophages, metformin specifically blunt ed secretion of proinflammatory cytokines, without inhibiting M1/M2 differentiation or activation. In a large treatment naive diabetes mellitus population cohort, we observed differences in the systemic inflammation marker, neutrophil to lymphocyte ratio, after incident treatment with either metformin or sulfonylurea monotherapy. Compared with sulfonylurea exposure, metformin reduced the mean log-transformed neutrophil to lymphocyte ratio after 8 to 16 months by 0.09 U (95% confidence interval, 0.02–0.17; P=0.00364). Following up these findings in a double-blind placebo controlled trial in nondiabetic heart failure (trial registration: NCT00473876), metformin suppressed plasma cytokines including the aging-associated cytokine CCL11 (C-C motif chemokine ligand 11).

Conclusion: We conclude that anti-inflammatory properties of metformin are exerted irrespective of diabetes mellitus status. This may accelerate investigation of drug utility in nondiabetic cardiovascular disease groups.

Clinical Trial Registration: Name of the trial registry: TAYSIDE trial (Metformin in Insulin Resistant Left Ventricular [LV] Dysfunction). URL: https://www.clinicaltrials.gov. Unique identifier: NCT00473876. (Circ Res. 2016;119:652-663. DOI: 10.1161/CIRCRESAHA.116.308445.)

Key Words: cardiovascular diseases diabetes mellitus heart failure inflammation metabolism metformin NF-kappa B

Metformin is the first-line drug in type 2 diabetes mellitus because compared with other type 2 diabetes mellitus treatments, in both clinical trials and observational studies, metformin monotherapy is associated with fewer adverse cardiovascular events,1,2 and in some studies, a reduced risk of cancer.3 The reasons for this relative benefit are unclear, and...
metformin’s molecular action is a vigorous area of current research. Metformin’s chemical properties include a strongly hydrophilic character, metal-binding properties, and a pKᵦ within the physiological pH range. The key clinical hallmark of metformin’s antihyperglycemic action is suppression of hepatic glucose gluconeogenesis. The most likely cellular effect underlying this response is inhibition of mitochondrial enzymes, including complex I in the electron transport chain. More recently, mitochondrial glycerophosphate dehydrogenase has been suggested as an alternative target. Mitochondrial inhibition activates AMP-activated protein kinase (AMPK), and recent work suggests that duodenal AMPK contributes toward effects of the drug on hepatic glucose production. Other studies indicate that metformin also suppresses glucose production by AMPK-independent mechanisms, but more broadly, AMPK may still contribute to metformin-dependent regulation of other aspects of metabolic control, such as lipogenic gene expression.

The mechanism(s) underlying metformin’s advantage in incidence of cardiovascular disease (CVD) are unlikely to depend on effects of the drug on hyperglycemia, which is controlled equally well by metformin and insulin secretagogues. In addition, in animals, metformin suppresses infarct size and adverse remodeling in diabetic and nondiabetic rodents and retards heart failure progression in nondiabetic dogs. In addition, in animals, metformin suppresses infarct size and retards heart failure progression in nondiabetic dogs. 22

Animal Care

Methods

Animal and Cell Studies

Metformin and rapamycin came from calbiochem, 5-aminomidazole-4-carboxamide riboside (AICAR) and A769662 (Tocris), tumor necrosis factor-α (TNF-α) (e-bioscience), recombinant CINC1/chemokine (C-X-C motif) ligand (CCLX) 1, C-C motif chemokine ligand (CCL)-1, interleukin (IL)-2, IL-4, stromal cell-derived factor and CCL22 (R&D systems), mouse IL-6 (Sigma), and recombinant mouse IL-1β (Life Technologies). The phospho-acetyl-CoA carboxylase Ser79 antibody was a generous gift from the DSTT (University of Dundee). The total acetyl-CoA carboxylase (Cat. number 3662), total AMPKα (2603), phospho-AMPKα Thr172 (2535), total S6 (2217), phospho-S6 Ser244/248 (2215), total p70 S6 kinase (2708), phospho-p70 S6 kinase Thr389 (9205), phospho-Raptor Ser 792 (2083), phospho inhibitor of kappa B kinase (IKK) α/β Ser176/177 (2078), IKKα/β Ser176/180 (2697), total IkB, pNF-κB, total IKKα, and total IKKβ (NF-κB sizer kit 9936) antibodies were from CST. Antisense horse radish peroxidase (31480) and antirabbit horse radish peroxidase (31460) both came from Thermo and antimouse horse radish peroxidase was from Calbiochem (JA1200). B6f1o5906 was generously gifted by Prof Sir Philip Cohen (Dundee).

Cell Culture and Lysis for Immunoblotting

All cells were grown in an incubator at 37°C and 5% CO₂. Primary mouse hepatocytes were extracted and maintained essentially as described previously.

Bone marrow–derived macrophages (BMDMs) were grown from mouse bone marrow in RPMI 1640 medium supplemented with 10% fetal bovine serum (Life Technologies) and 10-ng/mL macrophage colony-stimulating factor (R&D systems). Cells were given fresh medium and growth factor on day 3 of culture. On day 6, BMDM cultures were supplemented with 100-ng/mL interferon γ (for M1 differentiation; R&D systems), 20-ng/mL IL-4 (for M2 differentiation; R&D systems), or 100-ng/mL lipopolysaccharide (for activation; premium grade from Sigma, expected to activate toll-like receptor [TLR]-2 and TLR4) in the presence or absence of drug treatments for the final 24 hours.

Before SDS-PAGE, cells were lysed by scraping into buffer A (50 mmol/L Tris acetate pH 7.5, 1% (v/v) Triton X100, 1 mmol/L EDTA, 1 mmol/L EGTA, 0.27 mol/L sucrose, 50 mmol/L NaF, 1 mmol/L sodium orthovanadate, 10 mmol/L β-glycerophosphate, 5 mmol/L sodium pyrophosphate, 1 mmol/L benzamide, 0.2 mm/L phenylmethylsulfonyl fluoride, and 0.1% (v/v) β-mercaptoethanol) and then prepared for SDS-PAGE as described in the previous work. Immunoblot densitometry for each antibody was performed with Image Studio Lite version 5.2 (LI-COR). Each blot is representative of experiments performed at least 3x.

Glucose Assay

Treatment of cells for hepatocyte glucose production was performed essentially as described previously, using primary mouse hepatocytes plated in 12-well plates (1.25×10⁵ cells per well). Glucose production was determined after a 12-hour incubation period in glucose-free DMEM (11966; Life Technologies) supplemented with 1% pen/ strept. lactate (Sigma)/pyruvate (Life Technologies; 10:1 mmol/L), and 100 mmol/L dexamethasone (dex; Merck) with or without drugs/ cytokines under investigation. At the end of the incubation period of 12 hours, 500 µL of medium was collected and glucose concentration determined by GAGO assay (glucose [glucose oxidase]; Sigma) by a modified protocol scaled down to a 96-well plate format. Each column consists of data from at least 12 wells of cells, 6 each from 2 mice.

Real-Time-Polymerase Chain Reaction

Total RNA from primary mouse hepatocytes was extracted using QIAshredder (Qiagen) and Rneasy MINI KIT (Qiagen). cDNA was

### Nonstandard Abbreviations and Acronyms

| Abbreviation | Description |
|--------------|-------------|
| AICAR        | 5-aminimidazole-4-carboxamide riboside |
| AMPK         | AMP-activated protein kinase |
| BMDM         | bone marrow–derived macrophages |
| BMI          | body mass index |
| CCL          | C-C motif chemokine ligand |
| CVD          | cardiovascular disease |
| CXCL         | chemokine (C-X-C motif) ligand |
| DM           | diabetes mellitus |
| FIRI         | Fasting Insulin Resistance Index |
| IR           | insulin resistant |
| NFκB         | nuclear factor-κ-light-chain-enhancer of activated B cells |
| NLR          | neutrophil to lymphocyte ratio |
| TLR          | toll-like receptor |
| TNFα         | tumor necrosis factor-α |

Cameron et al | Anti-Inflammatory Effects of Metformin | 653 |
synthesized using QRTase Frie-Dnase kit (Promega) and ImProm-II Reverse Transcription System (Promega). Nuclease RNA II Total RNA isolation kit (Macherey-Nagel) was used to isolate RNA from macrophages. cDNA was synthesized using High Capacity cDNA Reverse Transcription Kit (4368814, Thermo Fisher Scientific). Real-time polymerase chain reaction was performed using the 7900HT Fast Real-Time PCR System (Applied Biosystems) using TaqMan 2x Universal PCR Master Mix (Applied Biosystems) and primer/probes mixes as stated (Applied Biosystems). Primer sets used were as follows: IL-6 Mm00446190_m1, CXCL1 Mm00247046_m1, 18S Hs03003531_g1, IL-1β Mm00434228_m1, CXCL2 Mm00436450_m1, peroxisome proliferator-activated receptor-y m18143222_m1, fatty acid synthase Mm00662319_m1, CCL2 Mm00436439_m1, CXCL12 Mm00445553_m1, TATA-binding protein Mm01277042_m1, and sterol regulatory element-binding protein 1c Mm00550338_m1. Cycling conditions were as follows: 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 s and 60°C for 1 minute. Expression is relative to 18s mRNA for hepatocytes and TATA-binding protein for macrophages (Applied Biosystems) using the 2-ΔΔCT method. Each column is composed of data from at least 3 separate experiments.

BMDM Analysis
BMDMs were harvested from culture plates using 4 mmol/L EDTA in PBS for 10 minutes at 37°C. Cells were washed in flow cytometry buffer (PBS with 2% fetal bovine serum and 1 mmol/L EDTA) and stained using the following antibodies (all BD Bioscience unless otherwise stated): F4/80 (BM8; e-bioscience), CD11c (HL3), CD206 (C068C2; Biolegend), CD68 (H.2F3), and CD40 (3/23). Fc block (4.4G2) was included in all stains. Data were acquired on a LSR II flow cytometer (Becton Dickinson) and analyzed using FlowJo software (TreeStar). BMDM culture supernatants were collected after 24-hour treatment with the differentiation or activation conditions. Levels of cytokines were quantified by standard sandwich ELISA using paired antibody kits (e-bioscience).

Validation in Clinical Patients
We validated the animal study findings in clinical patients utilizing 2 approaches: a retrospective population cohort study and a randomized placebo-controlled study of metformin. All patients provided written informed consent to participate in these clinical studies that were approved the local ethics committee.

Population Cohort Study: Metformin Exposure in DM Patients and Neutrophil to Lymphocyte Ratio
In the population cohort study, we investigated whether the anti-inflammatory signature of metformin could be detected in humans with DM, using the GoDARTS (Genetics of Diabetes Audit and Research in Tayside Scotland) DM register.28 We compared the effect of metformin and sulfonylureas on the neutrophil to lymphocyte ratio (NLR), a marker of inflammation derived from a combination of hematological components of the systemic inflammatory response29,30 that has recently been found to be a predictor of all-cause mortality and cardiac events.31 We analyzed data from type 2 diabetes mellitus patients recruited in Tayside, Scotland, UK, between October 1, 1997, and March 1, 2010. Of the 9205 subjects with DM within the GoDARTS study, we chose 3575 treatment naive patients who were either incident metformin users or incident sulfonylurea users (but not both) and noninsulin users. Incident use meant at least 6 months before first observed metformin/sulfonylurea prescription date during which they were observable for drugs. Of these 670 patients (mean [SD]: age, 65 [11] years; 54% men; 54% men) had derived NLR values both at baseline (up to 120 days before first metformin/sulfonylurea prescription) and follow-up (8–16 months after baseline). NLR was calculated as the ratio of the neutrophil:lymphocyte count, both obtained from the same blood sample. A total of 408 (74%) patients were treated with metformin and 172 (26%) with sulfonylurea. Multivariate linear and logistic regression models were run on the 8- to 16-month follow-up NLR against the treatment group, controlling for covariates including age, sex, and baseline NLR value.

Randomized Placebo-Controlled Study: Metformin Exposure and Cytokine Levels in Nondiabetic Heart Failure Patients
The anti-inflammatory effects of metformin were investigated in a randomly selected subset of patients who had participated in a double-blind, placebo-controlled study (NCT00473876) that had evaluated the impact of metformin on insulin resistant (IR) and exercise capacity in nondiabetic patients with congestive heart failure.32 Every patient had provided written informed consent before participation in this study, which was approved by the East of Scotland Research Ethics Service. The subset of patients selected for this study involved 33 nondiabetic IR congestive heart failure patients (mean age, 62±7.0 years; men, 85%; New York Heart Association class II/III/IV, 04/28/01/00) who were randomized to receive either 4 months of metformin (n=20; 2 g/d) or matching placebo (n=13). IR was defined by a fasting insulin resistance index (FIRI) of ≥2.7. The effect of metformin on plasma inflammatory cytokines was examined by investigating changes from baseline to final visit after 4 months in the study.

Cytokine Assay
Human plasma was analyzed using the Bio-Plex Pro Human Chemokine 40-Plex Panel (171-AK99MR2, Bio-Rad). The assay was performed following the manufacturer’s instructions using the Bio-Plex 200 system (Bio-Rad). Freeze–thaw cycling of samples was avoided to prevent cytokine degradation, and they were diluted 1:4 (12.5 μL of plasma) for the assay.

Statistical Analyses
Results in bar graphs are expressed as mean±SEM. Comparisons between groups were made by 1-way ANOVA with Dunnet or Tukey post hoc test using Prism. Differences were considered statistically significant if P<0.05: ***P<0.001, **P<0.01, and *P<0.05 unless otherwise stated. For studies on the plasma, statistical analyses of data were performed using SPSS 14.1. ANOVA and Pearson correlation coefficients were calculated.

Results
Metformin Inhibits TNF-α–Dependent NF-κB Inflammatory Signaling, Comparably With the Specific IKKβ Inhibitor BI605906
In primary mouse hepatocytes, the main target of metformin’s antihyperglycemic effects, we compared metformin with the specific IKKβ inhibitor BI605906.33 Metformin treatment for 3 hours suppressed TNF-α-induced degradation of the NF-κB negative regulator IκB, while modulating AMPK and mammalian target of rapamycin signaling in a dose-dependent manner (Figure 1A through 1C; all densitometry appears in the Online Data Supplement). The magnitude of the effect on IκB was comparable with BI605906 (Figure 1A and 1D). Unlike metformin, BI605906 did not suppress signaling downstream of mammalian target of rapamycin nor did it activate AMPK (Figure 1E and 1F). We were unable to detect any effect of rapamycin on NF-κB signaling either (Figure 1D), suggesting that the effect of metformin on NF-κB and mammalian target of rapamycin occurs independently. Consistent with these signaling results, TNF-α–dependent expression of CINC-1/CXCL1, CXCL2, IL-1β, and IL-6 was strongly inhibited by both metformin and BI605906 (Figure 1G through 1J).

AMPK-Independent Regulation of NF-κB in Primary Hepatocytes
To determine whether metformin directly regulated kinase activity that may mediate its effects on NF-κB signaling, a
Figure 1. Effect of metformin on nuclear factor-\(\kappa\)B (NF-\(\kappa\)B) signaling and gene expression. A–C, Primary hepatocytes were incubated in serum-free medium overnight and then stimulated for 3 h with or without 0.5 to 5 mmol/L metformin. For the last 15 min, cells were treated with or without 10 ng/mL tumor necrosis factor (TNF)-\(\alpha\). Cells were lysed and prepared for immunoblotting using antibodies as described in the Methods section of this article. In this figure and elsewhere, each blot is representative of experiments carried out at least 3×. D–F, Primary hepatocytes were incubated as in A–C, before stimulation for 3 h with or without 2 mmol/L metformin and TNF-\(\alpha\). In addition, cells were incubated with/without 10 \(\mu\)mol/L BI605906 or 100 nmol/L rapamycin as shown, before lysis and immunoblotting as described in the Methods section of this article. G–J, Primary hepatocytes were treated with or without 10 ng/mL TNF-\(\alpha\), 2 mmol/L metformin, or 10 \(\mu\)mol/L BI605906 for 8 h followed by cell lysis, RNA extraction, and preparation of cDNA for real-time-polymerase chain reaction using primer sets for individual genes shown as described in the Methods section of this article. ACC indicates acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; p-ACC, phospho–acetyl-CoA carboxylase; and pAMPK, phospho–AMP-activated protein kinase.
Dissociation of Anti-Inflammatory Responses From Effects of Metformin on Hepatic Glucose Production and Lipogenic Gene Expression

Metformin’s main antihyperglycemic effect is to reduce hepatic glucose production. To determine whether metformin-regulated cytokines directly altered glucose production, we incubated hepatocytes with and without metformin, IL-6, IL-1β, CXCL1, and TNFα. CXCL1 significantly increased glucose production (Figure 3A). In all groups, metformin reduced glucose production to below control levels (basal) in the presence or absence of cytokine. Incubation of hepatocytes with BI605906 did not mimic the effect of metformin, nor was there any modulation of metformin’s suppression of glucose production (Figure 3B).

Next, we compared the effect of metformin and BI605906 on lipogenesis, which is an another metabolic response known to be regulated by metformin. Proinflammatory cytokines including TNF-α are known to induce lipogenesis. This prompted us to study the effects of TNF-α on lipogenic genes steril regulatory element-binding protein 1c, peroxisome proliferator–activated receptor-γ, and fatty acid synthase, which are known to be regulated by metformin in hepatocytes.13,32,35 TNF-α significantly increased fatty acid synthase mRNA expression, with a trend toward increased expression of sterol regulatory element-binding protein 1c and peroxisome proliferator–activated receptor-γ (Figure 3C through 3E). Metformin reduced mRNA expression of all 3 genes and prevented TNF-α–induced increases. In contrast to the inflammatory genes, coinubcation of BI605906 and TNF-α increased lipogenic gene expression (Figure 3C through 3E). BI605906 alone did not alter sterol regulatory element-binding protein 1c, fatty acid synthase, or peroxisome proliferator–activated receptor-γ; however, this compound significantly augmented TNF-α–induced expression of each gene. This may be related to the existence of negative feedback loops in NF-κB signaling.33

Direct Anti-Inflammatory Effect of Metformin on Macrophage Cytokine Secretion

Our evidence that metformin inhibits inflammatory responses in hepatocytes independently of some metabolic actions prompted us to study inflammatory responses in extrahepatetic tissues. Macrophages may undergo classical proinflammatory M1 activation in response to cues including lipopolysaccharide and interferon γ. However, in response to agents including IL-13 and IL-4, they may become M2 cells, which are generally thought of as having anti-inflammatory or tissue repair actions.36 We studied the effects of metformin and another drug biguanide (structurally this drug is the same as metformin except that it lacks the 2 methyl groups present in metformin), which we have found previously acts similar to metformin on hepatocytes.6 We investigated 3 aspects: macrophage differentiation, activation, and secretion of cytokines. We measured effects on bone marrow–derived macrophage (BMDM) differentiation into M1 and M2 macrophages, using expression of CD11c as a marker of M1 differentiation and CD206 as a measure of M2 differentiation. In addition, we investigated macrophage activation in response to lipopolysaccharide, which acts on the toll-like receptor TLR4, increasing expression of CD69 and CD40. There was no significant effect of the drugs on expression of any of these markers (Figure 4A and 4B). As in hepatocytes, metformin suppressed IL-1β gene expression in macrophages (Online Figure IIIA), but somewhat reminiscent of the effect of BI605906 on lipogenic genes, metformin increased expression of the other cytokines we had studied in hepatocytes (Online Figure IIIB–IIID). We did, however, observe further drug-induced reductions when we measured cytokine secretion, to investigate macrophage activity and differentiation more directly. The 3 cytokines we studied were inflammatory cytokines IL-12p40, IL-6, and the anti-inflammatory cytokine IL-10 in these TLR-triggered cells. Both drugs reduced IL-12p40 and IL-6 secretion but were without effect on IL-10 secretion (Figure 4C through 4E).

Chronic Treatment of Hepatocytes With Low Doses of Metformin Triggers Anti-Inflammatory Signaling Responses Similar to Those Resulting From High-Dose Acute Treatment

Plasma levels of metformin in the clinical setting are understood to be in the low micromolar range. Consequently, metformin-treated individuals may have lower intracellular concentrations of metformin than in our cell experiments, but the duration of exposure will be much longer. Discrepancies in effective concentrations of metformin likely occur because of the length of exposure, as the drug must accumulate in active mitochondria over several hours. In hepatocytes, long-term (24 hours) effects of the drug on NF-xB signaling occurred at concentrations close to the physiological range and this was unaffected by genotype (Figure 5A through 5C).

To provide more insight into the site of metformin action, we investigated signaling further upstream of IKK (Figure 5A). We found that TNF-α–induced phosphorylation of the upstream kinase site p176/177 on IKKα/β was
suppressed by metformin. In supporting studies, we found that propanediimidamide, a close structural analogue of metformin that we have found does not inhibit the mitochondria,\(^6\) does not inhibit IκB degradation, nor does it suppress phosphorylation of IKKα/β (Figure 5A). Consistent with the notion that NF-κB signaling can respond to mitochondrial inhibition...
independently of AMPK, we found that the complex I inhibitor rotenone prevented TNF-α–dependent IκB degradation in both genotypes (Figure 5D).

**Anti-Inflammatory Effects of Metformin in a DM Population Cohort**

Next, we compared the effect of metformin and sulfonylureas on the NLR, a marker of inflammation that has recently been found to be a predictor of all-cause mortality and cardiac events.31 To test the hypothesis that metformin reduces inflammation using the GoDARTS diabetic cohort, we chose individuals prescribed metformin alone (without sulfonylurea or insulin) or sulfonylurea alone (without metformin or insulin), and for whom NLR measurements were available in the 120 days before first metformin/sulfonylurea prescription (the baseline measure) and 12 months after the first prescription (within a 8–16-month window). There were 498 people in metformin group and 172 in sulfonylurea group. Baseline characteristics of the 2 groups are shown in Table 1. Comparison...
of the 2 groups showed a significant effect of metformin exposure compared to sulfonylurea, with 12-month log-transformed NLR 0.09 lower in the metformin group (95% confidence interval [CI], 0.02–0.17; \( P = 0.01 \)), controlling for baseline values. This is equivalent to a 9% (95% CI, 2–15) lower geometric mean NLR. In addition, a logistic regression of 12-month NLR being lower than the baseline NLR gave an odds ratio of 1.83 (95% CI, 1.22–2.75; \( P = 0.0034 \)) for the metformin group compared with the sulfonylurea group (Tables 2 and 3). Body mass index (BMI) both nearest baseline and follow-up (4% missing) was not a significant variable (\( P = 0.7 \)), so was excluded. Inclusion of baseline HbA1c (19% missing) in the models resulted in similar effects. To examine the effect of metformin on high values on NLR, the models were rerun including only subjects with baseline NLR above the respective group median values (Tables 4 and 5). These showed a stronger metformin effect in the linear model, equivalent to a 15% (95% CI, 5–23) lower geometric mean NLR and an unchanged metformin effect for the logistic model, odds ratio of 1.91 (1.02–3.59). These results are summarized in Table 6.

To control for the different characteristics of the metformin and sulfonylurea groups, further analyses following propensity-score matching were performed. Nearest-neighbor one-to-one matching on DM duration, BMI, age, and angiotensin-converting enzyme exposure at baseline resulted in a reduced matched cohort of 318 (47% of original). Refitting the linear model using this cohort showed a similar effect of metformin exposure compared with sulfonylurea, with 12-month log-transformed NLR 0.10 lower in the metformin group (95% CI, 0.01–0.20; \( P = 0.03 \)). The logistic model for 12-month NLR lower than the baseline NLR gave an odds ratio of 1.53 for the metformin group compared with the sulfonylurea group; however, this effect was not statistically significant (95% CI, 0.93–2.52; \( P = 0.096 \)).

Effect of Metformin on Inflammation in Nondiabetic Heart Failure

Given evidence that the anti-inflammatory effects of metformin may be dissociated from some metabolic responses in cells and from glycemic responses in DM, we further investigated the anti-inflammatory effects of metformin in a placebo-controlled clinical trial of metformin in a group of nondiabetic IR heart failure patients.39 In this study, compared with placebo, metformin significantly improved FIRI and resulted in a significant reduction in weight loss of 1.9 kg and BMI. Metformin treatment also reduced the prespecified secondary end point of the slope of the ratio of minute ventilation:carbon dioxide production.39 We analyzed plasma from 33 patients who took part in this study and performed multivariate ANOVA on all 40 cytokines with treatment (with and without metformin, 20 allocated to metformin and 13 to
Figure 5. Effect of long-term metformin treatment on nuclear factor-κB (NF-κB) signaling responses in hepatocytes. A and B. Primary hepatocytes were treated as in Figure 1 with metformin or propanediimidamide (PDI) at the doses indicated except that the treatment time was 24 h. For the last 15 min, cells were treated with 10 ng/mL tumor necrosis factor (TNF)-α. In addition to antibodies used elsewhere, phosphorylation of inhibitor of kappa B kinase (IKK)α/β was investigated using the phosphospecific antibodies indicated. After cell lysis, SDS-PAGE and immunoblotting were performed as in Figure 1. C and D. Hepatocytes from wild-type (WT) and AMPK double-knockout (KO) livers treated as in A or with doses of rotenone for 45 min before cell lysis, SDS-PAGE and immunoblotting. E. Primary hepatocytes were treated in the presence or absence of the agents shown. Cells were treated with/witout metformin (2 mmol/L), C-C motif chemokine ligand (CCL)-11 (5 ng/mL), interleukin (IL)-2, IL-4, stromal cell–derived factor (SDF), and CCL22 (10 ng/mL) for 12 h, and glucose production was measured by GAGO (glucose [glucose oxidase]) assay as described in the Methods section of this article. ACC indicates acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; p-ACC, phospho–acetyl-CoA carboxylase; and pAMPK, phospho–AMP-activated protein kinase.
The 5 cytokines, CCL22 and CXCL12 (Table 8). Metformin improved insulin sensitivity as shown by significant reduction in FIRI (t=2.765, df=30.762; P<0.01) when an independent sample t test (equal variances not assumed) was performed; however, there was no significant correlation between change in FIRI and any change in the cytokines in the panel using a Pearson correlation. When a second correction for change in FIRI was applied, in addition to change in BMI, 4 of the 5 original cytokines remained significantly different with treatment (Table 7).

Most of the cytokines suppressed by metformin in plasma were not measurable in hepatocytes or macrophages and for those that could be measured, metformin did not inhibit their expression in these cell types (Online Figure IV). Similar to our earlier studies, these cytokines had little, if any, effect on inducing glucose production in hepatocytes and metformin could still suppress this parameter in their presence (Figure 5E). All details of cytokine changes, metabolic, hemodynamic, and other parameters of these patients are described in Online Tables I and II.

**Discussion**

We have used pharmacological and genetic approaches to isolate anti-inflammatory effects of metformin from those on glucose in cells, plasma, patient records, and in a placebo-controlled study. Initiating the study in hepatocytes, we separated signaling effects of metformin on the metabolic regulator AMPK from effects on inflammatory signaling. Although the AMPK activator AICAR induced similar effects to metformin on IκB degradation, AMPK was not required for these effects. In long-term treatment, effects of metformin on NF-κB signaling occurred at concentrations toward the physiological range, and in further studies, we found that propanediimidamide, a close structural analogue of metformin that does not inhibit the mitochondria, does not inhibit IκB degradation, nor does it increase phosphorylation of IKKα/β as is observed with metformin. Consistent with the possibility that NF-κB signaling can respond to

**Table 1. Baseline Measurements of GoDARTS (Genetics of Diabetes Audit and Research in Tayside Scotland) Diabetes Cohort**

| Variable                        | Metformin (n=498) | Sulfonylurea (n=172) | P Value |
|---------------------------------|-------------------|----------------------|---------|
| Age, y                          | 65 (57–72)        | 69 (61–76)           | 0.042   |
| Sex (% of men)                  | 55                | 51.2                 | 0.432   |
| Diabetes mellitus duration, y*  | 2.1 (0.2–5)       | 0.95 (0.1–4.2)       | 0.00193 |
| Body mass index, kg/m²*         | 32 (29–35.98)     | 27.2 (24.4–31.05)    | 2.26E–14|
| HbA1c, %*                       | 8.2 (7.6–9.1)     | 8.4 (7.5–9.6)        | 0.471   |
| Neutrophil to lymphocyte ratio* | 2.1 (1.5–2.62)    | 2.56 (1.988–3.89)    | 2.47E–06|
| Neutrophils (×10⁹/L)*           | 4.2 (3.3–5.5)     | 4.8 (3.75–6.225)     | 0.00103 |
| Lymphocytes (×10⁹/L)*           | 2.1 (1.7–2.8)     | 1.8 (1.4–2.3)        | 1.19E–05|
| Platelets (×10⁹/L)*             | 236 (199–280)     | 251.5 (198–305.5)    | 0.133   |
| C- reactive protein, mg/L*      | 10 (5–16.75)      | 10 (4.1–20)          | 0.854   |
| Creatinine, μmol/L*             | 86 (75–98)        | 94.5 (78–120.8)      | 0.000172|
| Bilirubin, μmol/L*              | 9 (7–13)          | 9 (7–11.75)          | 0.069   |
| Albumin, g/L*                   | 44 (42–45)        | 41 (38–43)           | 1.35E–10|
| Urea, mmol/L*                   | 5.8 (4.8–6.8)     | 6.6 (5.075–9.325)    | 0.000644|

**Table 2. Regression Coefficients of Linear Model (log-NLR)**

| Estimate      | SE       | 95% CI               | P Value |
|---------------|----------|----------------------|---------|
| Sex, men      | 0.054775 | 0.031656             | −0.00727 to 0.117 | 0.084038 |
| Age, y        | −0.035556| 0.012157             | −0.0594 to −0.0117 | 0.003567 |
| Age², y       | 0.000281 | 0.000095             | 9.51e–05 to 0.000467 | 0.003163 |
| log(NLR) at baseline | 0.498068 | 0.030933             | 0.437 to 0.559 | <10⁻⁵ |
| Group: metformin | −0.093859 | 0.037702             | −0.168 to −0.0200 | 0.013037 |

**Table 3. Regression Coefficients of Logistic Model (NLR_12<NLR_0)**

| Estimate      | SE       | 95% CI               | P Value |
|---------------|----------|----------------------|---------|
| Sex, men      | −0.2280  | 0.1703               | −0.562 to 0.106 | 0.1804 |
| Age, y        | 0.1450   | 0.0669               | 0.039 to 0.276 | 0.0302 |
| Age², y       | −0.0012  | 0.0005               | −0.00218 to −0.000133 | 0.0267 |
| log(NLR) at baseline | 1.9456   | 0.2128               | 1.528 to 2.363 | <10⁻⁵ |
| Group: metformin | 0.6054  | 0.2078               | 0.198 to 1.013 | 0.0036 |

CI indicates confidence interval; and NLR, neutrophil to lymphocyte ratio.
mitochondrial inhibition independently of AMPK, we found that metformin and rotenone each prevented TNF-α–dependent IxB degradation in an AMPK-independent manner. Considering information from these pharmacological and genetic experiments, our data indicate that metformin acts upstream of IKKα/β through an AMPK-independent mechanism dependent on mitochondrial inhibition. This mechanism is fully consistent with our other observations that metformin does not directly inhibit IKK in vitro. These studies do not exclude the possibility of AMPK-dependent mechanisms contributing to anti-inflammatory actions of metformin in other ways. Effects of metformin on anti-inflammatory signaling pathways were separable from other metabolic responses to the drug. Inhibition of NF-κB signaling had little effect, for example, on glucose production or lipogenic gene expression, 2 key metabolic actions of metformin. Moreover, addition of cytokines suppressed by metformin in hepatocytes, plasma, or macrophages did not block the effect of the drug on glucose production. Taken together, these results define a dual action of metformin, with anti-inflammatory actions occurring alongside known antihyperglycemic and other metabolic effects. These 2 strands are both likely to be triggered by a mitochondrial target of the drug.

The evidence that metformin can suppress inflammatory signaling independently of some of its metabolic effects led us to investigate nonhepatic anti-inflammatory responses. Previous studies have suggested that inflammatory signaling on macrophages influences insulin sensitivity in other tissues. Loss of the lipopolysaccharide receptor TLR4, for example, confers some protection from insulin resistance following a high-fat diet. In addition, M2 macrophages dominate in adipose tissue in lean mice, whereas M1 macrophages accumulate in adipose tissue during obesity and are thought to contribute to systemic insulin resistance.

At the level of gene expression, there were some differences between the effect of metformin in hepatocytes and macrophages although IL-1β was suppressed in both cell types. Studying cytokine secretion from macrophages, we found that metformin acted highly selectively to reduce proinflammatory cytokine secretion from activated macrophages, without affecting anti-inflammatory cytokine secretion and markers of macrophage differentiation and activation. This targeted mechanism may allow selective ablation of the ability of M1 macrophages to induce systemic insulin resistance in obesity. Taken together with the results in hepatocytes, this work suggests that metformin’s anti-inflammatory actions are likely to be qualitatively different from conventional NSAIDs.

We wished to establish whether the effects of metformin could be detected in humans and we started with a DM cohort. Investigating the GoDARTS patient database, we found evidence of metformin reducing subclinical inflammation as measured by NLR in patients. It is noteworthy that our findings support previous reports that metformin is capable of suppressing markers of inflammation such as high-sensitivity C-reactive protein in prediabetic individuals and TNF-α in IR individuals. NLR has recently been identified as a predictor of all-cause mortality and cardiovascular events, whereas previous studies demonstrated a substantial beneficial effect of metformin therapy on cardiovascular outcomes. Together, these results suggest that suppression of chronic inflammation

Table 4. Regression Coefficients of Linear Model: Baseline NLR>Median

| Estimate | SE      | 95% CI            | P Value |
|----------|---------|-------------------|---------|
| Sex, men | 0.1202  | 0.0427            | 0.0364 to 0.204 | 0.0052 |
| Age, y   | −0.0268 | 0.0149            | −0.0561 to 0.00241 | 0.0730 |
| Age², y  | 0.0002  | 0.0001            | −1.037e–05 to 0.000444 | 0.0623 |

| Group: metformin | Estimate | SE      | 95% CI            | P Value |
|------------------|----------|---------|-------------------|---------|
| −0.1596          | 0.0551   | −0.268 to −0.0517 | 0.0040   |

CI indicates confidence interval; and NLR, neutrophil to lymphocyte ratio.

Table 5. Regression Coefficients of Logistic Model: Baseline NLR>Median

| Estimate | SE      | 95% CI            | P Value |
|----------|---------|-------------------|---------|
| Sex, M   | −0.4841 | 0.2419            | −0.958 to −0.00992 | 0.0454 |
| Age, y   | −0.0090 | 0.0104            | −0.0294 to 0.0114 | 0.3869 |
| log(NLR) at baseline | 2.2827 | 0.4423            | 1.416 to 3.15 | <10⁻⁴ |
| Group: metformin | 0.6478 | 0.3219            | 0.0168 to 1.279 | 0.0442 |

CI indicates confidence interval; and NLR, neutrophil to lymphocyte ratio.

Table 6. Summary of GoDARTS (Genetics of Diabetes Audit and Research in Tayside Scotland) Analyses, Comparing NLR in Metformin and Sulfonylurea Groups

| Group Analyzed | 12-mo Geometric Mean NLR Metformin vs Sulfonylurea % Difference (95% CI) | 12-mo NLR<0 mo NLR Odds Ratio, Metformin vs Sulfonylurea (95% CI) |
|----------------|--------------------------------------------------------------------------|------------------------------------------------------------------|
| All subjects   | −9% (2–15)                                                               | 1.83 (1.22–2.75)                                                 |
| NLR above group median | −15% (5–23)                                                             | 1.91 (1.02–3.59)                                                 |

CI indicates confidence interval; and NLR, neutrophil to lymphocyte ratio.

Table 7. ANOVA of Heart Failure Cohort With Treatment (Without or With Metformin) as Main Factor With Covariate Analysis

| Change in Cytokine | Covariate | ΔBMI | ΔBMI and ΔFRI |
|--------------------|-----------|------|---------------|
| Eotaxin/CCL11       | R²(1,26)=9.881; P=0.004* | R²(1,26)=9.135; P=0.006* |
| IL-2               | R²(1,26)=9.089; P=0.006* | R²(1,26)=8.078; P=0.009* |
| IL-4               | R²(1,26)=8.324; P=0.008* | R²(1,26)=7.148; P=0.014 |
| MDC/CCL22          | R²(1,26)=9.887; P=0.004* | R²(1,26)=9.846; P=0.005* |
| SDF/CCL12          | R²(1,26)=16.468; P=0.000* | R²(1,26)=14.661; P=0.001* |

ΔBMI indicates body mass index; CCL, C-C motif chemokine ligand; CXCL, chemokine (C-X-C motif) ligand; FRI, Fasting Insulin Resistance Index; IL, interleukin; and SDF, stromal cell–derived factor-1.

Significance is taken as *P<0.01 (n=27).
by metformin might contribute to the difference in outcomes between these 2 treatment modalities.

Finally, given the evidence from cells that anti-inflammatory and metabolic effects of the drug can be separated, we studied a nondiabetic insulin-resistant heart failure cohort from a randomized controlled trial. Our research question was to determine whether metformin suppressed plasma cytokines. We observed a general trend of metformin treatment lowering cytokine concentrations. Correcting for change in BMI, 5 cytokines were significantly suppressed by metformin but only 2 of these, CCL22 and stromal cell–derived factor 1αβ, also correlated with change in BMI in follow-up analysis, suggesting that in individuals with established CVD, metformin exerts anti-inflammatory effects that are at least in part independent of BMI. Four of the 5 cytokines remained significant after additional correction for FIRI, and there was no significant correlation between change in FIRI and any of the cytokines in the panel using a Pearson correlation, even though metformin did reduce FIRI. Together these data strongly suggest that metformin has effects above and beyond the known effects on BMI and insulin sensitivity. The identity of these 5 cytokines signpost ways in which anti-inflammatory effects of metformin could exert DM-independent therapeutic effects in CVD. One earlier cohort study, for example, found that a Thr/Ala substitution in the CCL11 gene increases risk of myocardial infarction independently of BMI and DM.46 Blockade of CCL11 can suppress aspects of age-related cellular dysfunction,47 and it is possible that observed effects of metformin on mammalian longevity,48,49 where suppression of NF-κB is also observed,48 may owe at least in part to suppression of this cytokine. The other cytokines stromal cell–derived factor 1αβ, IL-2, IL-4, and CCL22 are each implicated in resolution of pancreatic β cell inflammation50–53 and stromal cell–derived factor 1αβ, IL-2, and IL-4 are additionally upregulated in plasma from type 2 DM individuals.54,55 Further work will be required to determine how the effects on macrophages and hepatocytes that we have measured contribute to the changes in plasma cytokines observed. Changes in other inflammatory cell types, particularly neutrophils given the change in NLR, or in cell–cell interactions, may need to be taken into account. Altogether our results are consistent with metformin exerting a potentially cardioprotective anti-inflammatory effect in patients with CVD, suppressing both age and metabolic inflammatory stress markers, independently of effects on BMI, insulin sensitivity, and without the onset of frank DM.

We recognize the limitations that are inherent in retrospective, nonrandomized, observational cohort data. It was impossible to account for all possible confounding influences that may have biased the observed differences between the groups considered. For example, the BMI of the 2 groups is different, consistent with historical prescribing patterns (Tables 7 and 8). We have sought to minimize these as far as practicable by 3 different sensitivity analyses. First, by using a multivariate model adjusting for potential confounders; second, by performing a propensity score–matched analysis; and third, we detected an anti-inflammatory signal in a randomized, double-blinded, placebo-controlled trial, providing definitive evidence of anti-inflammatory effects of metformin in this group of patients. The propensity score–matched analysis has been shown to eliminate as much as 90% of treatment bias in observational studies.46 Because of the small size of the clinical trial, this proof-of-concept study was designed and powered only to investigate the study-specific end point of peak oxygen uptake in patients with heart failure and not on clinical outcome. However, we have previously shown in a large population-based cohort study that patients with DM and heart failure who were treated with metformin alone or in combination with sulfonylureas were at significantly lower risk of all-cause mortality during 1 year and long-term follow-up than those who were treated with sulfonylurea alone.44 Our findings on metformin and inflammation will now similarly need to be confirmed in other patient cohorts.

In summary, cross-species evidence from cells, plasma, patient records, and a randomized placebo-controlled study strongly suggest that anti-inflammatory effects should be investigated further as a potentially important aspect of metformin’s clinical pharmacology that may particularly accelerate investigation of their utility in nondiabetic cohorts. There is overwhelming evidence that inflammation contributes to the development of CVD29 but counterbalancing this is evidence from meta-analysis of randomized control trials that existing NSAIDs tend to exacerbate risk of CVD.57 If inflammation is to be targeted successfully in CVD, new treatment paradigms will need to be established. It is likely, for example, that agents targeting only selected aspects of inflammation will need to be identified. Our work identifying discrete anti-inflammatory effects of metformin on cell signaling and plasma parameters independently of DM supports ongoing and prospective investigation into repurposing metformin in a broader spectrum of patients with CVD.

**Acknowledgments**

We thank Dr Kashyap Patel (Exeter) for demonstrating hepatocyte extraction. In addition, Dr Andy Cassidy and Dr Ritu Sharma (both Dundee) assisted set-up of real-time polymerase chain reaction.

**Sources of Funding**

G. Rena acknowledges funding from MRC (MR/K012924/1) and the Diabetes UK RW and JM Collins studentship, supporting C. Forteath (12/0004625). S.C. Fagerholm acknowledges funding from the Academy of Finland and Biocentrum Helsinki. M. Foretz acknowledges funding from the French National Research Agency (ANR-10-ESVI-002) and the CNRS. G. Rena acknowledges funding from the British Heart Foundation (grant number PG/06/143/21897 and PG/14/4/30539). A.K.F. Wong acknowledges support from the
British Heart Foundation (grant number PG/06/143/21897). M. Mohan. acknowledges fellowship support from the British Heart Foundation (grant number PG/14/3/30539). V.L. Morrison was supported by the Ella and Georg Ehrnrooth foundation and D.K. Balfour acknowledges funding from Alzheimer’s Research UK, grant number ART-EXT-2010–2. C. Beall is an RD Lawrence Fellow (Diabetes UK grant number: 13/00004647).

Disclosures

None.

References

1. Evans JM, Ogston SA, Emсли-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. *Diabetologia*. 2006;49:930–936. doi: 10.1007/s00125-006-0176-9.

2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*. 1998;352:854–865.

3. Evans JM, Donnelly LA, Emсли-Smith AM, Alesri DS, Morris AD. Metformin and reduced risk of cancer in diabetic patients. *BMJ*. 2005;330:1304–1305. doi: 10.1136/bmj.38415.708634.F7.

4. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? *Diabetologia*. 2015;58:1898–1906. doi: 10.1007/s00125-013-2991-0.

5. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. *Clin Sci (Lond)*. 2012;122:253–270. doi: 10.1042/CS20110386.

6. Logie L, Harthill J, Patel K, Bacon S, Hamilton DL, Macrae K, McDougall G, Wang HH, Xue L, Jiang H, Sakamoto K, Prescott AR, Rena G. Cellular responses to the metal-binding properties of metformin. *Diabetes*. 2012;61:1423–1433. doi: 10.2373/dbi11-0961.

7. Repiščak P, Erhardt S, Rena G, Paterson MJ. Biomolecular mode of action of metformin in relation to its copper binding properties. *Bioschemistry*. 2014;53:787–795. doi: 10.1021/bi401444n.

8. Quan X, Uddin R, Heiskanen A, Parvmi M, Nilson K, Donolato M, Hansen MF, Rena G, Boisen A. The copper binding properties of metformin–QCM-D, XPS and nanobead agglomeration. *Chem Commun (Camb)*. 2015;51:17313–17316. doi: 10.1039/c5cc04321b.

9. Rena G, Pearson ER, Sakamoto K. Molecular action and pharmacogenetics of metformin: current understanding of an old drug. *Diabetes Management*. 2012;2:439–452.

10. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex I of the mitochondrial respiratory chain. *Biochem J*. 2000;348 Pt 3:607–614.

11. El-Mir MY, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vincor F; Centers for Disease Control and Prevention and the American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation*. 2003;107:499–511.

12. Isoda K, Young JL, Zilzik A, MacFarlane LA, Tsuibo N, Gerdes N, Schönbeck U, Libby P. Metformin inhibits proinflammatory responses and nuclear factor-κBα in human vascular wall cells. *Arterioscler Thromb Vasc Biol*. 2006;26:611–617. doi: 10.1161/01.ATV.0000201938.78044.75.

13. Pinato DJ, Stavracas C, Flynn MJ, Forster MD, O’Callahan SM, Seckl MJ, Kristeteil RS, Olmos D, Turnbull SJ, Blagden SP. An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. *PLoS One*. 2014;9:e83279. doi: 10.1371/journal.pone.0083279.

14. Wang X, Zhang G, Jiang X, Zhu H, Lu Z, Xu L. Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: a meta-analysis of observational studies. *Atherosclerosis*. 2014;234:206–213. doi: 10.1016/j.atherosclerosis.2014.03.003.

15. Bhatta K, Hwang BJ, Dewi RE, Twaddell W, Goloubeva OG, Wong KK, Saxena NK, Biswal S, Girnun GD. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. *Cancer Prev Res (Phila)*. 2012;5:544–552. doi: 10.1158/1940-6207.CAPR-11-0228.

16. Clark K, Peggie M, Plater L, Sorcek RJ, Young ER, Madwed JB, Hough J, McIver EG, Cohen P. Metformin inhibits proinflammatory responses and nuclear factor-κBα in human vascular wall cells. *Arterioscler Thromb Vasc Biol*. 2001;21:5–14.

17. Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vincor F; Centers for Disease Control and Prevention and the American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation*. 2003;107:499–511.

18. Isoda K, Young JL, Zilzik A, MacFarlane LA, Tsuibo N, Gerdes N, Schönbeck U, Libby P. Metformin inhibits proinflammatory responses and nuclear factor-κBα in human vascular wall cells. *Arterioscler Thromb Vasc Biol*. 2006;26:611–617. doi: 10.1161/01.ATV.0000201938.78044.75.

19. Pinato DJ, Stavracas C, Flynn MJ, Forster MD, O’Callahan SM, Seckl MJ, Kristeteil RS, Olmos D, Turnbull SJ, Blagden SP. An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. *PLoS One*. 2014;9:e83279. doi: 10.1371/journal.pone.0083279.

20. Wang X, Zhang G, Jiang X, Zhu H, Lu Z, Xu L. Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: a meta-analysis of observational studies. *Atherosclerosis*. 2014;234:206–213. doi: 10.1016/j.atherosclerosis.2014.03.003.

21. Bhatta K, Hwang BJ, Dewi RE, Twaddell W, Goloubeva OG, Wong KK, Saxena NK, Biswal S, Girnun GD. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. *Cancer Prev Res (Phila)*. 2012;5:544–552. doi: 10.1158/1940-6207.CAPR-11-0228.

22. Clark K, Peggie M, Plater L, Sorcek RJ, Young ER, Madwed JB, Hough J, McIver EG, Cohen P. Novel cross-talk within the IKK family controls inflammatory responses and nuclear factor-κBα in human vascular wall cells. *Arterioscler Thromb Vasc Biol*. 2001;21:5–14.

23. Pinato DJ, Stavracas C, Flynn MJ, Forster MD, O’Callahan SM, Seckl MJ, Kristeteil RS, Olmos D, Turnbull SJ, Blagden SP. An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. *PLoS One*. 2014;9:e83279. doi: 10.1371/journal.pone.0083279.

24. Wang X, Zhang G, Jiang X, Zhu H, Lu Z, Xu L. Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: a meta-analysis of observational studies. *Atherosclerosis*. 2014;234:206–213. doi: 10.1016/j.atherosclerosis.2014.03.003.

25. Bhatta K, Hwang BJ, Dewi RE, Twaddell W, Goloubeva OG, Wong KK, Saxena NK, Biswal S, Girnun GD. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. *Cancer Prev Res (Phila)*. 2012;5:544–552. doi: 10.1158/1940-6207.CAPR-11-0228.

26. Clark K, Peggie M, Plater L, Sorcek RJ, Young ER, Madwed JB, Hough J, McIver EG, Cohen P. Novel cross-talk within the IKK family controls inflammatory responses and nuclear factor-κBα in human vascular wall cells. *Arterioscler Thromb Vasc Biol*. 2001;21:5–14.
38. Zhang J, Clark K, Lawrence T, Peggie MW, Cohen P. An unexpected twist to the activation of IKKβ: TAK1 primes IKKβ for activation by autophosphorylation. *Biochem J.* 2014;461:531–537. doi: 10.1042/B012140444.

39. Wong AK, Symon R, AlZadjali MA, Ang DS, Ogsston S, Choy A, Petrie JR, Struthers AD, Lang CC. The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. *Eur J Heart Fail.* 2012;14:1303–1310. doi: 10.1093/eurheartj/hfs106.

40. Poggi M, Bastelica D, Gual P, Iglesia MA, Gremeaux T, Knauf C, Peiretti F, Verdier M, Juhan-Vague I, Tanti JP, Burcelin R, Alessi MC. C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. *Diabetologia.* 2007;50:1267–1276. doi: 10.1007/s00125-007-0654-8.

41. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. *J Clin Invest.* 2007;117:175–184. doi: 10.1172/JCI29881.

42. Goldberg RB, Temprosa MG, Mather KJ, Orchard TJ, Kitabchi AE, Watson KE; Diabetes Prevention Program Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and sPAA levels in the diabetes prevention program except in those who develop diabetes. *Diabetes Care.* 2014;37:2253–2260. doi: 10.2337/dc13-2471.

43. Evia-Viscarra ML, Rodea-Montero ER, Apolinar-Jiménez E, Muñoz-Noriega N, García-Morales LM, Leaños-Pérez C, Figueroa-Barrón M, Sánchez-Fierros D, Reyes-García JG. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. *J Pediatr Endocrinol Metab.* 2012;25:41–49. doi: 10.1515/jpem-2011-0469.

44. Evans JM, Doney AS, AlZadjali MA, Ogsston SA, Petrie JR, Morris AD, Struthers AD, Wong AK, Lang CC. Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. *Am J Cardiol.* 2010;106:1006–1010. doi: 10.1016/j.amjcard.2010.05.031.

45. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med.* 2008;359:1579–1589. doi: 10.1056/NEJMoa0806470.

46. Zee CY, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Lee RT, Ridker PM. Thromine for alanine substitution in the eotaxin (CCL11) gene and the risk of incident myocardial infarction. *Atherosclerosis.* 2004;175:91–94. doi: 10.1016/j.atherosclerosis.2004.01.042.

47. Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. *Nature.* 2011;477:90–94. doi: 10.1038/nature10357.

48. Bannister CA, Holden SE, Jenkins-Jones S, Morgan CL, Halcox JP, Schernthaner G, Mukherjee J, Currie CJ. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. *Diabetes Obes Metab.* 2014;16:1165–1173. doi: 10.1111/dom.12354.

49. Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. *Nat Commun.* 2013;4:2192. doi: 10.1038/ncomms3192.

50. Hulme MA, Wasserfall CH, Atkinson MA, Brusko TM. Central role for interleukin-2 in type 1 diabetes. *Diabetes.* 2012;61:14–22. doi: 10.2337/db11-1213.

51. Bischoff L, Alvarez S, Dai DL, Soukhatcheva G, Orban PC, Vercher CB. Cellular mechanisms of CCL22-mediated attenuation of autoimmune diabetes. *J Immunol.* 2015;194:3054–3064. doi: 10.4049/jimmunol.1400567.

52. Cameron MJ, Arreaza GA, Zucker P, Chensue SW, Strieter RM, Chakrabarti S, Delovich TL. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. *J Immunol.* 1997;159:4686–4692.

53. Yano T, Liu Z, Donovan J, Thomas MK, Habener JF. Stromal cell derived factor-1 (SDF-1)/CXCL12 attenuates diabetes in mice and promotes pancreatic beta-cell survival by activation of the prosurvival kinase Akt. *Diabetes.* 2007;56:2946–2957. doi: 10.2337/db07-0291.

54. Ip B, Cifone N, Zhu M, Kuchibhatla R, Azer M, McDonnell M, Apovian C, Lauffenburger D, Nikolajczyk B. An inflammatory T cell signature predicts obesity-associated type 2 diabetes (HUM3P.262). *J. Immunol.* 2015;194:121.122

55. Derakhshan R, Aribabadi MK, Ahmadi Z, Karimabad MN, Salehabadi VA, Abedinzadeh M, Khorramdelazad H, Balaei P, Kennedy D, Hassanshahi G. Increased circulating levels of SDF-1 (CXCL12) in type 2 diabetic patients are correlated to disease state but are unrelated to polymorphism of the SDF-1β gene in the Iranian population. *Inflammation.* 2012;35:900–904. doi: 10.1007/s10753-011-9391-8.

56. D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. *Stat Med.* 1998;17:2265–2281.

57. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschanne B, Villiger PM, Egger M, Jiani P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. *BMJ.* 2011;342:c7086.

---

**Novelty and Significance**

**What Is Known?**

- Observational studies have repeatedly shown benefit of metformin in reducing incidence of CVD events in DM.
- Inflammation is understood to contribute to CVD cause, but it has been difficult to harness anti-inflammatory effects for CVD therapy.

**What New Information Does This Article Contribute?**

- Metformin exhibits an anti-inflammatory action in cells and patients, in addition to its known antihyperglycemic effects.
- Anti-inflammatory effects of metformin are exerted irrespective of diabetes status, providing a nonempirical rationale for further testing of the drug in nondiabetic CVD.

Inflammation is understood to contribute to CVD cause, but existing NSAIDs have shown limited utility in CVD treatment. This suggests that other agents, with different anti-inflammatory mechanisms, need to be identified for CVD. Observational studies have repeatedly shown benefit of metformin in reducing incidence of CVD events in diabetes, which do not seem to depend on antihyperglycemic effects alone. In this study, we investigated anti-inflammatory effects of metformin, as these may contribute to the CVD benefit of this drug. We find that this drug acts by inhibiting the NF-κB signaling pathway upstream of IKKβ. In further work, we find that anti-inflammatory effects of metformin are exerted irrespective of diabetes status, including suppression of the ageing-related cytokine CCL11 in a nondiabetic heart failure cohort. These results suggest that metformin suppresses chronic inflammation by a different mechanism to NSAIDs and provide a nonempirical rationale for further testing of the drug in nondiabetic CVD.
Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status
Amy R. Cameron, Vicky L. Morrison, Daniel Levin, Mohapradeep Mohan, Calum Forteath, Craig Beall, Alision D. McNeilly, David J.K. Balfour, Terhi Savinko, Aaron K.F. Wong, Benoit Viollet, Kei Sakamoto, Susanna C. Fagerholm, Marc Foretz, Chim C. Lang and Graham Rena

Circ Res. 2016;119:652-665; originally published online July 14, 2016;
doi: 10.1161/CIRCRESAHA.116.308445

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circres.ahajournals.org/content/119/5/652
Free via Open Access

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2016/07/14/CIRCRESAHA.116.308445.DC1.html

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/
Supplementary Materials

Expanded Methods

I. Animal and Cell Studies

Metformin and rapamycin came from Calbiochem, AICAR and A769662 (Tocris), TNF-α (e-bioscience), recombinant CINC1/CXCL1, CCL-11, IL-2, IL-4, SDF and CCL22 (R&D systems), mouse IL-6 (Sigma) and recombinant mouse IL-1β (Life Technologies). The phospho-acetyl-CoA carboxylase (ACC) Ser79 antibody was a generous gift from the DSTT (University of Dundee). The total ACC (Cat. number 3662), total AMPKα (2603), phospho-AMPKα Thr172 (2535), total S6 (2217), phospho-S6 Ser240/244 (2215), total p70 S6 kinase (2708), phospho-p70 S6 kinase Thr389 (9205), phospho-Raptor Ser 792 (2083), phospho IKKα/β Ser176/177 (2078), IKKα/β Ser176/180 (2697), total IκB, pNF-κB, total IKKα and total IKKβ (NF-κB sampler kit 9936) antibodies were from CST. Anti-sheep HRP (31480) and antirabbit HRP (31460) both came from Thermo and anti-mouse HRP was from Calbiochem (JA1200). BI605906 was a generous gift from Prof Sir Philip Cohen.

Animal Care

C57BL/6 female mice (Charles River, 8-41 weeks) were maintained under a 12 hours:12hours light:dark cycle (holding room lights on at 06:00; off at 18:00) at 22±1°C and 50% humidity. Mice had ad libitum access to standard chow diet (7.5% fat, 75% carbohydrate and 17.5% protein by energy (RM1 diet; Special Diet Services) and water. All animal care protocols and procedures were performed in accordance with current regulations.

AMPKα1α2-null (AMPK KO) mice were maintained under a 12-hour light/12-hour dark cycle with free access to water and standard mouse diet (in terms of energy: 65% carbohydrate, 11% fat, 24% protein). These AMPK catalytic subunit deficient mice were generated as previously described (1). All procedures were performed in accordance with the principles and guidelines established in the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (Council of Europe, ETS no. 123, 1991).
**Hepatocyte Extraction**

Mice were killed by cervical dislocation following guidelines set out by the Animals (Scientific Procedures) Act 1986. An incision into the abdomen was followed by dissection of the skin, abdominal cavity and diaphragm to expose the liver, kidney, inferior vena cava and portal vein. The superior vena cava was clamped to isolate the hepatic system and the inferior vena cava was cannulated just above the kidney with a 25G butterfly needle and clamped in place. Immediately after cannulation, the portal vein was cut. Successful cannulation was determined when the liver cleared quickly of blood and became pale throughout. The liver was perfused with 50ml pre-warmed perfusion buffer (137mM NaCl, 7mM KCl, 0.7mM Na₂HPO₄, 10mM HEPES pH 7.65 filter sterilized (0.2 µm) with 0.1% EDTA 0.5M pH 8 added just prior to use) at a rate of 5ml/min. After 10 min, the liver was perfused with 50ml digestion buffer (perfusion buffer without EDTA with 5.1mM CaCl₂ and 20mg collagenase (from Clostridium histolyticum type IV, Sigma)); added at a rate of 5ml/min. After digestion, the liver was excised from the abdominal cavity and transferred to a cell culture hood in a 10cm dish. The liver was resuspended in 10ml of plating media (440ml M199 + Glutamax (1x), Invitrogen; 5ml Pen/Strep (100x), Invitrogen; 6.7ml BSA (7.5%), Invitrogen; 50ml FBS (foetal bovine serum); 7.7µl Insulin Actrapid (100U/ml), Novo Nordisk; 100µl T3 (thyroid hormone 1mM stock), Sigma; 25µl Dexamethasone (10mM stock), Merck) and the hepatocytes isolated by gently agitating the liver. Cells were filtered through a 100 µm cell strainer and this process was repeated 4 more times until a final volume of 50ml was obtained. Hepatocytes were pelleted by centrifugation at 400 rpm for 5 min using no acceleration or braking. The supernatant was discarded and the cell pellet resuspended in 25ml plating media by gentle inversion. Cell viability was determined by 0.04% Trypan blue staining and the cell number determined using a haemocytometer. Cell viability of >90% was required for experimental use.

**Cell Culture and Lysis for Immunoblotting**

All cells were maintained in an incubator at 37°C and 5% CO₂. For lysate and RT-PCR experiments, primary mouse hepatocytes were plated in 6-well plates (2.5 x 10⁵ cells/well in 2ml media) while for glucose assay experiments, primary mouse hepatocytes were plated in 12-well plates (1.25 x 10⁵ cells/well in 1ml media). After 4
hours, plating media was removed, cells were washed with warmed PBS and overnight media (500ml M199 + Glutamax (1x); 5ml Pen/Strep (100x); 25µl Dexamethasone (10mM stock)) was added at 2ml per well. Cells were incubated overnight and experiments were performed the following day.

BMDMs were grown from mouse bone marrow in RPMI 1640 medium supplemented with 10% FBS (Life Technologies) and 10ng/ml M-CSF (R&D systems). Cells were given fresh medium and growth factor on day 3 of culture. On day 6, BMDM cultures were supplemented with 100ng/ml IFNy (for M1 differentiation; R&D systems), 20ng/ml IL-4 (for M2 differentiation; R&D systems), or 100ng/ml LPS (for activation; premium grade from Sigma, expected to activate TLR2 and TLR4) in the presence or absence of drug treatments for the final 24h.

Prior to SDS-PAGE, cells were lysed by scraping into buffer A: (50mM Tris acetate pH7.5, 1% (w/v) Triton X100, 1mM EDTA, 1mM EGTA, 0.27M sucrose, 50mM NaF, 1mM sodium orthovanadate, 10mM β-glycerophosphate, 5mM sodium pyrophosphate, 1mM benzamidine, 0.2mM phenylmethylsulfonyl fluoride (PMSF) and 0.1% (v/v) β-mercaptoethanol) then prepared for SDS-PAGE as follows. The lysates were centrifuged at 13 000 g for 15 min, and the supernatants were removed. Protein concentration was determined by Bradford assay (Bio-Rad). The supernatant was loaded in equal amounts of protein and subjected to 4-20% gradient SDS-PAGE and subsequently were transferred to nitrocellulose membranes. Primary antibody incubations were performed at dilutions recommended by the manufacturer or determined by us in 5% milk TBS-T. All incubations were done at 4°C, overnight after a 1 hr block in 5% milk TBS-T. The secondary antibody was used at 1:5000 dilution for 1 hr at room temperature. Proteins were visualised using the enhanced chemiluminescence (ECL) system (Amersham) onto X-ray film (Kodak). Immunoblot densitometry for each antibody was performed with Image Studio Lite version 5.2 (LI-COR). Each blot is representative of experiments carried out at least three times.

Glucose Assay

Treatment of cells for hepatocyte glucose production was performed using primary mouse hepatocytes plated in 12-well plates (1.25 x 10^5 cells/well in 1ml media).
Glucose production was determined after a 12 hour incubation period in 750µl glucose-free DMEM (11966; Life Technologies) supplemented with 1% Pen/Strep, lactate (Sigma)/pyruvate (Life Technologies) (10:1 mM) and 100nM dexamethasone (dex; Merck) with or without drugs/cytokines under investigation. At the end of the incubation period of 12 hours, 500µl of medium was collected and glucose concentration determined by GAGO assay (GAGO-20; Sigma) by a modified protocol scaled down to a 96-well plate format. 50µl of sample medium followed by 100µl assay reagent was added to each well with no time delay. Following incubation at 37°C for 30 minutes, 100µl 12N H2SO4 was added to each well and mixed using a multi-well pipette. Absorbance was measured at 540 nm. Each column consists of data from at least 12 wells of cells, six each from two mice.

RT-PCR

Primary mouse hepatocytes were incubated for 8 hours in 1ml glucose-free DMEM (11966; Life Technologies) supplemented with 1% pen/strep, lactate (Sigma)/pyruvate (Life Technologies) (10:1 mM) and 100nM dexamethasone (dex; Merck) with or without drugs under investigation. After this incubation period, media was removed and cells were washed once with warmed PBS. 350µl of Buffer RLT from the Rneasy MINI KIT (Qiagen) plus 10% β-mercaptoethanol was added to each well. Plates were then placed on ice for 10 min, followed by a cell harvest and samples were snap-frozen immediately in LN2. Total RNA was extracted using QIAshredder (Qiagen) and Rneasy MINI KIT (Qiagen) as per the manufacturer’s instructions. cDNA was synthesized from 1µg RNA using RQ1 Rnase-Free Dnase kit (Promega) and ImProm-II Reverse Transcription System (Promega). cDNA was diluted in nuclease-free water 1:10 prior to use.

Nucleospin RNA II Total RNA isolation kit (Macherey-Nagel) was used to isolate RNA from macrophages. cDNA was synthesized from 0.5µg RNA using High Capacity cDNA Reverse Transcription Kit (4368814, Thermo Fisher Scientific). cDNA was diluted in nuclease-free water 1:2 prior to use.

Real-time PCR was carried out using the 7900HT Fast Real-Time PCR System (Applied Biosystems) using TaqMan 2x Universal PCR Master Mix (Applied Biosystems) and primer/probes mixes as stated (Applied Biosystems). Primer sets
used were: IL-6 Mm00446190_ml; CXCL1 Mm04207460_m1; 18S Hs03003631_g1; IL-1β Mm00434228_m1; CXCL2 Mm00436450_m1; PPARγ Mm01184322_m1; FASN Mm00662319_m1; CCL22 Mm00436439_ml; CXCL12 Mm00445553_ml; TBP Mm01277042_m1 and SREBP-1c Mm00550338_m1. Cycling conditions were: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Expression is expressed relative to 18s mRNA for hepatocytes and TBP for macrophages (Applied Biosystems) using the 2^ΔΔCt method. Control samples were set at a value of 100% and results for all experimental samples were graphed as relative expression compared to control. Each column is composed of data from at least three separate experiments.

**BMDM studies**

BMDMs were harvested from culture plates using 4mM EDTA in PBS for 10min at 37°C. Cells were washed in flow cytometry buffer (PBS with 2% FBS and 1mM EDTA) and stained using the following antibodies (all BD Bioscience unless stated): F4/80 (BM8; e-bioscience), CD11c (HL3), CD206 (C068C2; Biolegend), CD69 (H1.2F3) and CD40 (3/23). Fc block (4.4G2) was included in all stains. Data were acquired on a LSR II flow cytometer (Becton Dickinson) and analysed using FlowJo software (TreeStar). BMDM culture supernatants were collected after 24 hours treatment with the differentiation or activation conditions. Levels of cytokines were quantified by standard sandwich ELISA using paired antibody kits (e-bioscience), according to the manufacturer's instructions.

**Statistical Analyses**

Results in bar graphs are expressed as mean ± SEM. Comparisons between groups were made by one-way ANOVA with Dunnett's or Tukey post-hoc test using Prism. Differences were considered statistically significant if P was less than 0.05. *** denotes p<0.001; ** denotes p<0.01 and * denotes p<0.05. For studies on the plasma, statistical analyses of data were performed using SPSS 14.1. ANOVA and Pearson correlation coefficients were calculated.

**II. Validation in Clinical Patients**
Population Cohort Study: Diabetes Patient Metformin Exposure and Neutrophil-to-Lymphocyte Ratio (NLR).

Sample Ascertainment

Patients were ascertained from the Diabetes Audit and Research in Tayside Scotland (DARTS) study, which has previously been described in detail (2). In brief, all the participants were linked through to the Health Informatics Centre Database to retrieve validated prescribing information, clinical information system, all haematological and biochemistry data and the Scottish Care Information–Diabetes Collaboration (SCI-DC) (REF) that provide additional clinical phenotypic data back to 1992. Prospective longitudinal data were also collected on these patients. The study was approved by the Tayside Regional Ethics Committee, and informed consent was obtained from all subjects since 1997 to DNA and serum collection as part of the Wellcome Trust United Kingdom Type 2 Diabetes Case Control Collection. Over 17,000 subjects have participated in this Genetics of DARTS (Go-DARTS) study till date, of whom over 9,000 have diabetes.

Hematological Measurements.

We analysed the electronically linked records of routine laboratory investigations of all the participants from the regional biochemistry and hematological database. The total and differential leucocyte counts (including the neutrophils and lymphocytes) were determined from peripheral venous blood samples using an automated Siemens’ high-volume hematology analyzer, the ADVIA® 2120i System (peroxidase method) (3). NLR was calculated as the ratio between (percentage of) neutrophils and total lymphocyte counts in the study subjects.

Statistical Analysis

For the population cohort study, characteristics of patients with or without metformin therapy were compared by the chi-square test for categorical variables and by the t test or Mann-Whitney U test for continuous variables as appropriate. The effect of metformin therapy on NLR were examined together with the significant differences found at baseline using linear and logistic regression analysis. The following covariates were included: age, sex, HbA1c, BMI, duration of followup, prior
hospitalisation for COPD, Atrial Fibrillation or Hypertension, and baseline NLR. To minimize confounding influences, we performed two different sensitivity analysis. First, by using a multivariate model adjusting for potential confounders; second we determined a propensity score using a logistic regression model to control for the different characteristics of the metformin and sulfonylurea groups. A P-value of <0.05 was considered significant and all statistical analysis for this cohort study were performed using R for windows (v3.2.0).

**Randomised Placebo Controlled Study**

The effect of metformin on plasma inflammatory cytokines were further investigated in a subset of chronic heart failure (CHF) patients who had participated in a double-blind, placebo-controlled study of metformin, which has previously been described in detail (4). In brief, this study was designed and powered to evaluate the impact of metformin on IR and its effects on exercise capacity in non-diabetic IR patients with CHF. Every patient who participated in this study, provided written informed consent prior to participation in this study, which was approved by the East of Scotland Research Ethics Service (www.clinicaltrials.gov: NCT00473876). In this study we had shown that metformin treatment significantly improved IR but had no significant effect on the primary endpoint of exercise capacity, as measured by peak VO₂. However, metformin treatment did result in a significant improvement in the minute ventilation – carbon dioxide production relationship (VE/VCO₂ slope), a pre-specified secondary endpoint of this proof of concept study which is of prognostic significance in patients with CHF, and in some studies, it has outperformed peak VO₂ (5).

**Cytokine Assay**

We analysed plasma from 33 non-diabetic insulin resistant heart failure patients who took part in a placebo controlled clinical trial of metformin (4). The plasma was analysed using the Bio-Plex Pro Human Chemokine 40-Plex Panel (171-AK99MR2, Bio-Rad). The assay was performed following the manufacturer’s instructions using the Bio-Plex 200 system (Bio-Rad). Freeze-thaw cycling of samples was avoided to prevent cytokine degradation and they were diluted 1:4 (12.5µl of plasma) for the assay.

**References**
(1) Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B: Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-2369.

(2) Morris AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung RT, Newton RW, MacDonald TM: The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 1997;315:524-528

(3) ADVIA 2120i Hematology System with Autoslide. SIEMENS Healthineers website. http://www.healthcare.siemens.com/hematology/systems/advia-2120-hematology-system-with-autoslide. Updated September 9, 2015. Accessed July 7, 2016.

(4) Wong AKF, Symon R, Alzadjali MA, Ang DSC, Ogston S, Choy AM, Petrie JR, Struthers AD, Lang CC: The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. European Journal of Heart Failure 2012;14:1303-1310

(5) Arena R, Myers J, Aslam SS, Varughese EB, Peberdy MA. Peak VO2 and VE/VCO2 slope in patients with heart failure: a prognostic comparison. Am Heart J 2004; 147: 354–360.
### Supplementary Table I. Cytokine measurements

| Cytokine (pg/ml)         | Placebo (n=13) | Metformin (n=20) |
|--------------------------|----------------|------------------|
|                          | Average | SD   | Average | SD   |
| CCL21/6Ckine             | 5454.29 | 2067.61 | 5890.92 | 1853.73 |
| BCA-1/CXCL13             | 28.52   | 9.54   | 35.02   | 13.22   |
| CTACK/CCL27              | 1723.32 | 583.41 | 1973.63 | 815.37   |
| ENA-78/CXCL5             | 642.91  | 213    | 781.07  | 321.26   |
| Eotaxin/CCL11            | 51.4    | 13.67  | 60.8    | 17.69    |
| Eotaxin-2/CCL24          | 685.11  | 518.81 | 640.79  | 402.68   |
| Eotaxin-3/CCL26          | 56.27   | 18.48  | 74.93   | 60.97    |
| Fractalkine/CX3CL1       | 172.05  | 61.95  | 237.93  | 93.3     |
| GCP-2/CXCL6              | 20.34   | 8.37   | 26.27   | 14.34    |
| GM-CSF                   | 128.91  | 50.39  | 137.67  | 52.51    |
| Gro-α/CXCL1              | 348.61  | 83.78  | 336.15  | 76.27    |
| Gro-β/CXCL2              | 153.61  | 74.54  | 235.74  | 178.19   |
| I-309/CCL1               | 83.83   | 17.2   | 92.43   | 18.49    |
| IFNγ                     | 64.35   | 20.88  | 75.98   | 27.42    |
| IL-1β                    | 7.53    | 3.66   | 9.33    | 3.84     |
| IL-2                     | 15.96   | 5.21   | 18.87   | 6.48     |
| IL-4                     | 32.19   | 7.45   | 33.4    | 9.48     |
| IL-6                     | 14.14   | 3.89   | 17.81   | 8.58     |
| IL-8/CXCL8               | 14.19   | 4.16   | 16.9    | 4.72     |
| IL-10                    | 46.74   | 21.99  | 54.49   | 22.46    |
| IL-16                    | 329.73  | 120.54 | 364.8   | 130.41   |
| IP-10/CXCL10             | 173.62  | 67.61  | 206.57  | 114.88   |
| I-TAC/CXCL11             | 18.02   | 6.86   | 23.33   | 7.83     |
| MCP-1/CCL2               | 69.92   | 33.76  | 86.03   | 52.74    |
| MCP-2/CCL8               | 56.84   | 21.19  | 70.44   | 38.9     |
| MCP-3/CCL7               | 126.6   | 35.08  | 146.64  | 53.26    |
| MCP-4/CCL13              | 77.59   | 46.32  | 69.26   | 39.3     |
| MDC/CCL22                | 1014.65 | 290    | 1151.86 | 505.54   |
| MIF                      | 6303.03 | 5822.99| 5681.16 | 3323.86  |
| MIG/CXCL9                | 296.66  | 136.95 | 404.71  | 277.22   |
| MIP-1α/CCL3              | 10.5    | 2.02   | 12.22   | 3.69     |
| MIP-1β/CCL15             | 7487.28 | 3978.97| 7716.92 | 4125.49  |
| MIP-3α/CCL20             | 34.9    | 79.52  | 37.84   | 43.88    |
| MIP-3β/CCL19             | 353.04  | 252.2  | 463.93  | 308.82   |
| MPIF-1/CCL23             | 446.78  | 221.81 | 494.74  | 211.13   |
| SCYB16/CXCL16            | 503.06  | 216.96 | 567.01  | 228.79   |
| SDF-1α+β/CXCL12          | 1257.91 | 423.96 | 1487.04 | 500.84   |
| Cytokine (pg/ml) |  | Placebo (n=13) |  | Metformin (n=20) |  | BMI (p value) |  | BMI & FIRI (p value) |
|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
|                  | Average | SD     | Average | SD     | Average | SD     |                  |                  |
| CCL21/6Ckine     | 99.20    | 756.47 | 55.16   | 2595.81 | 0.857   | 0.8   |
| BCA-1/CXCL13     | 3.92     | 7.29   | 2.34    | 14.28   | 0.036   | 0.029 |
| ENA-78/CXCL5     | 29.79    | 148.93 | -60.30  | 375.81  | 0.02    | 0.025 |
| Eotaxin/CCL11    | 5.18     | 8.94   | -0.36   | 17.00   | 0.004   | 0.006 |
| Eotaxin-2/CCL24  | 32.73    | 258.03 | -21.23  | 210.01  | 0.309   | 0.356 |
| Eotaxin-3/CCL26  | 6.54     | 13.67  | -11.50  | 54.48   | 0.038   | 0.053 |
| Fractalkine/CX3CL1| 0.93    | 56.10  | -25.89  | 107.44  | 0.085   | 0.081 |
| GCP-2/CXCL6      | 0.91     | 6.29   | 1.05    | 13.11   | 0.169   | 0.216 |
| GM-CSF           | 1.52     | 34.36  | 3.15    | 55.77   | 0.051   | 0.05  |
| Gro-α/CXCL1      | 11.01    | 54.90  | 5.89    | 80.00   | 0.101   | 0.106 |
| Gro-β/CXCL2      | 32.80    | 56.92  | 9.41    | 120.75  | 0.317   | 0.365 |
| IL-309/CCL1      | 6.16     | 10.89  | -0.69   | 17.79   | 0.011   | 0.014 |
| IFNγ             | 6.28     | 16.04  | -1.85   | 29.38   | 0.019   | 0.025 |
| IL-1β            | 0.16     | 2.90   | -0.96   | 4.15    | 0.116   | 0.098 |
| IL-2             | 1.47     | 3.17   | -0.95   | 6.96    | 0.006   | 0.009 |
| IL-4             | 1.33     | 4.55   | -2.67   | 11.90   | 0.008   | 0.014 |
| IL-6             | 0.86     | 3.43   | 2.75    | 14.94   | 0.022   | 0.027 |
| IL-10            | 6.79     | 14.29  | -4.43   | 27.19   | 0.019   | 0.024 |
| IL-16            | 32.62    | 82.96  | -19.07  | 149.55  | 0.013   | 0.021 |
| IP-10/CXCL10     | -3.82    | 52.93  | 16.13   | 118.54  | 0.958   | 0.893 |
| I-TAC/CXCL11     | 2.22     | 7.06   | 3.73    | 13.73   | 0.989   | 0.955 |
| MCP-1/CCL2       | 12.78    | 26.27  | 5.34    | 35.48   | 0.039   | 0.055 |
| MCP-2/CCL8       | 9.01     | 16.58  | -2.92   | 38.04   | 0.048   | 0.071 |
| MCP-3/CCL7       | 13.07    | 31.37  | -7.03   | 55.42   | 0.025   | 0.029 |
| MCP-4/CCL13      | -3.31    | 25.83  | 3.02    | 37.95   | 0.377   | 0.418 |
| MDC/CCL22        | 93.18    | 244.23 | -47.75  | 453.81  | 0.004   | 0.005 |
| MIF              | -1711.46 | 5475.63| -829.75 | 3572.37 | 0.436   | 0.464 |
| MIG/CXCL9        | 52.40    | 128.26 | -3.84   | 200.65  | 0.016   | 0.019 |
| MIP-1α/CCL3      | 0.72     | 1.66   | -0.52   | 2.67    | 0.013   | 0.013 |
| MIP-1β/CCL15     | -300.03  | 2502.48| 515.34  | 4045.71 | 0.505   | 0.368 |
| MIP-3α/CCL20     | -16.84   | 61.17  | -4.44   | 45.65   | 0.832   | 0.991 |
| MIP-3β/CCL19     | 97.36    | 212.33 | -77.06  | 343.62  | 0.018   | 0.024 |
| MPIF-1/CCL23     | -16.10   | 95.08  | -29.21  | 177.39  | 0.26    | 0.214 |
| SCYB16/CXCL16    | -11.35   | 114.84 | 30.26   | 203.08  | 0.083   | 0.11  |
| SDF-1α+β/CXCL12  | 103.67   | 198.81 | -49.25  | 409.72  | 0.0    | 0.001 |
| TARC/CCL17       | 29.45    | 72.26  | -20.89  | 96.02   | 0.022   | 0.03  |
### Supplementary table II. Metabolic, haemodynamic and other characteristics of patients

|                          | Placebo (n=13) | Metformin (n=20) | p value |
|--------------------------|----------------|------------------|---------|
| **Sex**                  | Male 12; Female 1 | Male 16; Female 4 |         |
| **Age**                  | 64.23 ± 6.99 | 62.70 ± 7.04 | 0.408   |
| **Metabolism Parameters**|                |                  |         |
| Body Mass Index          | 29.37 ± 5.11 | 30.19 ± 5.23 | 0.319   |
| Insulin (mU/L)           | 22.63 ± 11.54 | 27.47 ± 15.29 | 0.144   |
| Glucose (mmol/L)         | 5.37 ± 0.42  | 5.61 ± 0.66  | 0.331   |
| Fasting Insulin Resistance Index (log) | 4.90 ± 2.57 | 6.32 ± 3.92 | 0.134   |
| **Severity of Heart Failure** |            |                  |         |
| Brain Natriuretic Peptide (pg/ml) | 116.27 ± 131.98 | 139.09 ± 197.95 | 0.750   |
| Ejection Fraction (%)    | 28.82 ± 8.29 | 37.29 ± 7.93 | 0.016   |
| **Haemodynamic Conditions** |            |                  |         |
| Resting Systolic Blood Pressure (mmHg) | 116.54 ± 21.05 | 107.60 ± 9.68 | 0.101   |
| Resting Diastolic Blood Pressure (mmHg) | 75.15 ± 10.38 | 69.35 ± 7.15 | 0.178   |
| Resting Heart Rate       | 70.08 ± 21.22 | 68.60 ± 14.44 | 0.992   |
| Peak VO₂ (mL/kg/min)     | 18.02 ± 5.94 | 19.72 ± 4.75 | 0.776   |
| VE/VO₂ slope             | 30.65 ± 5.31 | 31.64 ± 6.03 | 0.244   |
| Total exercise duration (s) | 954.15 ± 355.64 | 1063.80 ± 204.51 | 0.469   |

Significance taken as * p < 0.01.
Change after 4 months metformin treatment

|                      | Placebo (n=13) | Metformin (n=20) | p value |
|----------------------|----------------|------------------|---------|
|                      | Average        | Average          |         |
|                      | SD             | SD               |         |
| **Metabolism Parameters** |                |                  |         |
| Body Mass Index      | 0.46           | -1.16            | 0.000   |
| Insulin (mU/L)       | 0.92           | -6.39            | 0.044   |
| Glucose (mmol/L)     | -0.02          | -0.29            | 0.042   |
| Fasting Insulin Resistance Index (log) | 0.26 | -1.81 | 0.029 |
| **Severity of Heart Failure** |            |                  |         |
| Brain Natriuretic Peptide (pg/ml) | 17.26 | -22.24 | 0.383 |
| Ejection Fraction (%) | -0.89          | -1.03            | 0.681   |
| **Haemodynamic Conditions** |            |                  |         |
| Resting Systolic Blood Pressure (mmHg) | -7.15 | 0.80 | 0.049 |
| Resting Diastolic Blood Pressure (mmHg) | -4.69 | -0.45 | 0.177 |
| Resting Heart Rate   | 1.00           | 2.70             | 0.451   |
| Peak VO₂ (mL/kg/min) | 1.25           | -0.91            | 0.334   |
| VE/VCO₂ slope        | 1.86           | -4.52            | 0.029   |
| Total exercise duration (s) | 7.08 | -22.75 | 0.671 |

**Supplementary figure legends**

**Supplementary Figure I. Densitometry of blots in main figure 1**
Densitometry was carried out as described in the methods to quantify data obtained in western blots. Bars significantly different from the respective control treatment (+/- TNFα) are shown, ***p<0.001, **p<0.01, *p<0.05. N=3 except for IκBa and pACC, N=4

**Supplementary Figure II. Densitometry of blots in main figure 2**
Densitometry was carried out as described in the methods to quantify data obtained in western blots. In experiments comparing wild-type (WT) and knockout (KO) genotype, black bars denote WT genotype, grey bars denote KO genotype. Bars significantly different from the respective control treatment (+/- TNFα) are shown,
***p<0.001, **p<0.01, *p<0.05, except in knockout experiments, where significance between genotypes is depicted. N=3

**Supplementary Figure III. Effect of metformin on gene expression in macrophages: genes regulated in hepatocytes**
Macrophages were treated with or without 100ng/ml LPS +/- 2mM metformin for 8h followed by cell lysis, RNA extraction and preparation of cDNA for RTPCR using primer sets for individual genes shown, as described in the methods. Bars significantly different from control treatment, or between two annotated bars are shown, ***p<0.001, *p<0.05

**Supplementary Figure IV. Effect of metformin on gene expression in macrophages and hepatocytes: genes changed by metformin in human plasma**
Macrophages (a,b) were treated with/without 100ng/ml LPS +/- 2mM metformin, while hepatocytes (c) were treated with/without 10ng/ml TNFα +/- 2mM metformin or 10mM BI605906 as shown, for 8h followed by cell lysis, RNA extraction and preparation of cDNA for RTPCR using primer sets for individual genes shown, as described in the methods. Bars significantly different from control treatment, or between two annotated bars are shown, ***p<0.001, **p<0.01, *p<0.05

**Supplementary Figure V. Densitometry of blots in main figure 5**
Densitometry was carried out as described in the methods to quantify data obtained in western blots. In experiments comparing wild-type (WT) and knockout (KO) genotype, black bars denote WT genotype, grey bars denote KO genotype. Bars significantly different from the respective control treatment (+/- TNFα) are shown, ***p<0.001, **p<0.01, *p<0.05, except in knockout experiments, where significance between genotypes is depicted. N=3
Supplementary Fig. II

**D**

[Graph showing the fold change of kDa in response to various concentrations of metformin and TNFα.]

**D**

[Graph showing the fold change of pACC in response to various concentrations of metformin and TNFα.]

**D**

[Graph showing the fold change of pAMPK in response to various concentrations of metformin and TNFα.]
Supplementary Fig. IV

MACROPHAGES

A

Fold Change in CXCL12

0 1 2 3

LPS Met (2 mM)

0 + + ns

B

Fold Change in CCL22

0 10 20 30

LPS Met (2 mM)

0 + + ns

HEPATOCYTES

C

Fold Change in CXCL12

0 1 2 3 4

Basal TNFα Met Met+TNFα BI BI+TNFα

* ns
Supplementary Fig. V

C

\[ \text{pAMPK (fold change)} \]

C

\[ \text{pACC (fold change)} \]

C

\[ \text{L-Br (fold change)} \]

- + - + - + - + - + - + - + - + - + + TNF\alpha

Metformin (mM)
